The shadow of generic challenges has consistently loomed over copyright’s iconic viagra drug, Viagra, sparking questions about the future of similar pharmaceutical investments. While early times saw impressive gains, the intellectual property lapse has allowed the way for cheaper alternatives, likely lowering earnings and presenting a significant